Costs and cost-effectiveness of the Kerala pilot screening programme for diabetic retinopathy in the public health system.

IF 2.8 3区医学 Q1 OPHTHALMOLOGY

Eye Pub Date : 2024-09-03 DOI:10.1038/s41433-024-03304-w

Raphael Wittenberg, Robert Anderson, Stuart Redding, Bipin Gopal, Rajeev Sadanandan, Vasudeva Iyer Sahasranamam, Simon George, Lakshmi Premnazir, Gopalakrishnan Netuveli, Jyotsna Srinath, Radha Ramakrishnan, Dolores Conroy, Sobha Sivaprasad

{"title":"Costs and cost-effectiveness of the Kerala pilot screening programme for diabetic retinopathy in the public health system.","authors":"Raphael Wittenberg, Robert Anderson, Stuart Redding, Bipin Gopal, Rajeev Sadanandan, Vasudeva Iyer Sahasranamam, Simon George, Lakshmi Premnazir, Gopalakrishnan Netuveli, Jyotsna Srinath, Radha Ramakrishnan, Dolores Conroy, Sobha Sivaprasad","doi":"10.1038/s41433-024-03304-w","DOIUrl":null,"url":null,"abstract":"Background/objectives: The Government of Kerala initiated a pilot screening programme for diabetic retinopathy in 16 Family Health Centres in Thiruvananthapuram district in 2019 in collaboration with the ORNATE India project. The evaluation of this pilot included a study of its costs and cost-effectiveness to inform decisions about extending the programme throughout Kerala.Subjects/methods: The participants comprise all 5307 people who were screened for diabetic retinopathy under the pilot programme for whom data could be collected.Results: The costs of the pilot programme are estimated at INR 11.3 million (including INR 1.9 million costs to individuals) and the benefits at 514 QALYs, slightly over one QALY per person treated. The cost per QALY was INR 22,000, which is well below India's Gross National Income per person.Conclusions: Kerala's 2019 pilot screening programme for diabetic retinopathy was highly cost-effective.","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03304-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/objectives: The Government of Kerala initiated a pilot screening programme for diabetic retinopathy in 16 Family Health Centres in Thiruvananthapuram district in 2019 in collaboration with the ORNATE India project. The evaluation of this pilot included a study of its costs and cost-effectiveness to inform decisions about extending the programme throughout Kerala.

Subjects/methods: The participants comprise all 5307 people who were screened for diabetic retinopathy under the pilot programme for whom data could be collected.

Results: The costs of the pilot programme are estimated at INR 11.3 million (including INR 1.9 million costs to individuals) and the benefits at 514 QALYs, slightly over one QALY per person treated. The cost per QALY was INR 22,000, which is well below India's Gross National Income per person.

Conclusions: Kerala's 2019 pilot screening programme for diabetic retinopathy was highly cost-effective.

查看原文本刊更多论文

喀拉拉邦公共卫生系统糖尿病视网膜病变试点筛查计划的成本和成本效益。

背景/目标：喀拉拉邦政府与印度 ORNATE 项目合作，于 2019 年在 Thiruvananthapuram 地区的 16 个家庭保健中心启动了糖尿病视网膜病变筛查试点项目。对该试点项目的评估包括对其成本和成本效益的研究，以便为在喀拉拉邦全境推广该项目提供决策依据：参与者包括在试点项目中接受糖尿病视网膜病变筛查并能收集到数据的所有 5307 人：试点计划的成本估计为 1130 万印度卢比（包括 190 万印度卢比的个人成本），收益为 514 QALY，略高于每人治疗一个 QALY。每个 QALY 的成本为 22,000 印度卢比，远低于印度的人均国民总收入：结论：喀拉拉邦 2019 年糖尿病视网膜病变试点筛查计划具有很高的成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Eye 医学-眼科学

CiteScore

6.40

自引率

5.10%

发文量

481

审稿时长

3-6 weeks

期刊介绍： Eye seeks to provide the international practising ophthalmologist with high quality articles, of academic rigour, on the latest global clinical and laboratory based research. Its core aim is to advance the science and practice of ophthalmology with the latest clinical- and scientific-based research. Whilst principally aimed at the practising clinician, the journal contains material of interest to a wider readership including optometrists, orthoptists, other health care professionals and research workers in all aspects of the field of visual science worldwide. Eye is the official journal of The Royal College of Ophthalmologists. Eye encourages the submission of original articles covering all aspects of ophthalmology including: external eye disease; oculo-plastic surgery; orbital and lacrimal disease; ocular surface and corneal disorders; paediatric ophthalmology and strabismus; glaucoma; medical and surgical retina; neuro-ophthalmology; cataract and refractive surgery; ocular oncology; ophthalmic pathology; ophthalmic genetics.